ModifiedUnitedHealthcarePolicy CSNCT0705.08

Prostate Surgeries and Interventions (for North Carolina Only)

Clinical coverage policy for prostate surgical and minimally invasive interventions for UnitedHealthcare members in North Carolina, specifying which procedures are considered medically necessary versus unproven/not medically necessary and referencing InterQual criteria where applicable.

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for North Carolina Only)

Policy CodePolicy CSNCT0705.08

Change TypeMaterial revisions to coverage stance, indications, and code list

Effective DateJul 1, 2025

Next Review DateN/A

Key ActionWhen requesting prior authorization, document failed conservative/medical therapy and indication-specific justification including baseline IPSS, Qmax, prostate volume, and counseling on comparative outcomes.

SourceLink

POLICY UPDATE CHANGES

Removed coverage criteria for transperineal placement of biodegradable material.

Updated Prostatic Urethral Lift indication language to include treatment of symptoms due to urinary outflow obstruction secondary to BPH, including lateral, with or without median lobe hyperplasia, in men 45 years of age or older.

Replaced language to state transurethral water jet ablation for malignant prostate tissue and all other indications not listed as proven is unproven and not medically necessary due to insufficient evidence.

Revised position on prostate artery embolization (PAE) to be proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints or anesthesia risk.

Added CPT codes 51721, 53865, 53866, 55881, and 55882 to applicable codes.

Multipleprocedures addressed

NC only

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Code listcodes provided

No RCTs for cryocryotherapy RCTs

~14.8 ptsaquablation IPSS improvement

Low/Insufficientevidence certainty

Coverage Criteria and Evidence Summary

inv-01: Transurethral ablation — covered with InterQual criteria

For medical necessity clinical coverage criteria, refer to InterQual CP: Procedures, Prostatectomy, Transurethral Ablation.

Transurethral ablation of the prostate is proven and medically necessary in certain circumstances; medical necessity clinical coverage criteria are referenced to InterQual CP: Procedures, Prostatectomy, Transurethral Ablation.

Refer to InterQual for specific criteria

inv-02: Cryoablation — limited coverage

Covered only in limited circumstances; documentation that criteria are met is required.

Cryoablation for recurrent prostate cancer: Cryoablation of the prostate is proven and medically necessary for recurrent prostate cancer diagnosed by biopsy. For other indications (including initial primary treatment of localized prostate cancer) cryoablation is unproven and not medically necessary due to low‑quality and heterogeneous evidence.

Refer to InterQual CP: Procedures, Cryoablation, Prostate for clinical criteria; lack of RCTs and heterogeneous reporting limit evidence strength.

inv-03: Prostatic urethral lift — covered with specific contraindications

Covered when ALL of the following are met:

PUL FDA‑labeled indications: Prostatic urethral lift (PUL) is proven and medically necessary when ALL of the following are met: treating urinary outflow obstruction secondary to benign prostatic hyperplasia (including lateral, with or without median lobe hyperplasia) in men aged ≥45 years; and none of the following are present: prostate volume >100 cc; urinary tract infection; urethral conditions preventing insertion of the delivery system into the bladder; urinary incontinence due to incompetent sphincter; current gross hematuria.Age ≥45; Prostate volume ≤100 cc

Must follow FDA‑labeled indications, contraindications, warnings, and precautions.

inv-04: Transurethral water jet ablation — covered for BPH

Covered for treatment of LUTS due to BPH when criteria below are met; other indications are not covered.

Aquablation (transurethral water jet ablation): Transurethral water jet ablation of the prostate is proven and medically necessary for resection/removal of prostate tissue to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia. Use for malignant prostate tissue and other indications is unproven and not medically necessary.Typical trial prostate volume eligibility 30–80 mL (some series up to 150 cc)

Key RCT evidence compares Aquablation to TURP with follow‑up to 5 years; document baseline IPSS, Qmax, prostate volume and prior therapies.

inv-05: PAE — limited coverage

Covered for select patients after documentation of eligibility and counseling about comparative outcomes versus TURP.

PAE indications: Prostate artery embolization (PAE) is proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints (e.g., prostate size) or anesthesia risk (e.g., comorbidities), or for persistent gross hematuria originating from the prostate. PAE is unproven and not medically necessary for other indications.

Document prior medical therapy attempts, prostate volume, baseline IPSS/QoL, Qmax, PVR, and counseling about higher retreatment rates and generally inferior objective functional outcomes versus TURP.

inv-06: Unproven / Not medically necessary procedures

The following procedures or indications are considered unproven or not medically necessary due to insufficient evidence of safety and/or efficacy.

Unproven / Not medically necessary procedures: High‑energy water vapor thermotherapy for malignant prostate tissue; transperineal focal laser ablation (FLA/TPLA) for many indications outside trials; insertion of temporary prostatic urethral stent; ablation of malignant prostate tissue by magnetic field induction; transurethral drug‑coated balloon dilation (Optilume) beyond trial indications pending comparative data; and transurethral thermal ultrasound ablation (TULSA) are considered unproven and not medically necessary for the listed indications due to insufficient evidence of safety and/or long‑term effectiveness.

Some technologies (e.g., Optilume) have promising single‑arm or sham‑controlled data but lack comparative long‑term evidence versus established therapies; TULSA added to unproven list in policy revision.

inv-07: Prostatic Urethral Lift (PUL) — evidence context

Evidence summary and trial‑based eligibility observations for PUL:

PUL evidence summary: Randomized and prospective trial evidence, including a blinded sham‑controlled RCT, demonstrates durable symptomatic improvement up to 5 years and favorable recovery and sexual function preservation in selected patients. Trials commonly enrolled men ≥50 years with IPSS >12, Qmax thresholds (≤12–15 mL/s), and prostate volumes typically 30–80 cc.IPSS >12; Qmax ≤12–15 mL/s; prostate volume ~30–80 cc

Comparative studies show TURP may be superior on some objective flow metrics; document baseline IPSS, Qmax, and prostate volume when requesting coverage.

inv-08: Aquablation — evidence context

Evidence summary for Aquablation and typical study limitations:

Aquablation evidence summary: A multicenter double‑blind randomized trial and subsequent prospective studies show Aquablation provides similar IPSS and uroflow improvements to TURP up to 5 years, with possible advantages in ejaculatory preservation and low retreatment rates; limitations include trial size, follow‑up attrition, manufacturer funding in some studies, and prostate size restrictions (most RCTs limited to ≤80 mL though separate series report outcomes for larger prostates).Prostate volume commonly 30–80 mL in RCTs; some series 80–150 cc

Document baseline IPSS, Qmax, prostate volume, and prior therapies for authorization.

inv-09: Cryoablation — evidence context

Cryoablation evidence limitations relevant to coverage decisions:

Cryoablation evidence summary: Systematic reviews identify mostly observational studies with few randomized trials and heterogeneous reporting; RCT evidence is limited and low quality, creating uncertainty about oncologic outcomes and long‑term effectiveness beyond recurrent disease where biopsy‑proven recurrence supports use.

Additional high‑quality research is needed; cryoablation considered proven for biopsy‑documented recurrent prostate cancer only.

inv-10: PAE — evidence context

PAE evidence highlights and selection considerations:

PAE evidence summary: Systematic reviews and randomized trials report that PAE yields perioperative advantages (less blood loss, shorter hospitalization) and similar patient‑reported symptom improvements to TURP in some studies, but PAE generally has inferior objective functional outcomes and higher retreatment rates; evidence certainty ranges from low to moderate. PAE may be appropriate for patients who are poor surgical candidates or have large prostates.

Counsel patients about higher retreatment risk (e.g., ~21% requiring TURP within 2 years in one RCT) and uncertain long‑term comparative efficacy.

inv-11: PAE — coverage considerations

Coverage considerations to apply when evaluating PAE requests:

PAE coverage considerations: PAE may be considered medically necessary for symptomatic BPH when the individual has failed medical therapy or is a poor candidate for TURP AND has been counseled regarding comparative outcomes versus TURP (PAE often offers symptomatic improvement but generally inferior objective measures and higher retreatment rates).

Require documentation of prior medical management, prostate volume, IPSS/QoL, Qmax, PVR, and rationale why TURP or other standard procedures are contraindicated or inappropriate.

inv-12: TPLA / FLA — coverage considerations

TPLA/FLA evidence and selection guidance:

TPLA/FLA coverage considerations: Transperineal focal laser ablation (TPLA/FLA) has insufficient evidence for long‑term effectiveness and safety; randomized trials demonstrate inferiority to TURP on some efficacy measures while showing superior preservation of antegrade ejaculation. Routine use for localized prostate cancer or BPH is not recommended outside clinical trials or prospective comparative studies.

Consider restriction to clinical trials or highly selected patients after informed consent regarding uncertain oncologic and long‑term outcomes.

inv-13: Coverage stance by technology

Summary coverage stance across selected emerging technologies:

Transperineal Laser Ablation (TPLA): Evidence is insufficient to establish long‑term effectiveness and safety; RCTs show TPLA may preserve antegrade ejaculation but are inferior on several efficacy outcomes (Qmax, IPSS) and limited by small sample sizes and short follow‑up.

Further large RCTs needed.

Temporary urethral stents (iTind): Available evidence includes RCTs and observational studies with mixed results; sustained symptom improvement reported up to 3–4 years in some studies but comparative long‑term data versus established therapies is limited.

Applicability to larger prostates, median lobe, and prior prostate surgery is unclear.

Ablation of malignant prostate tissue by magnetic field induction: Insufficient evidence — literature limited to early phase trials with feasibility data and notable procedural challenges; not recommended outside trials.

Experimental; further trials required.

inv-14: Optilume clinical evidence and eligibility observed in trials

Observed eligibility criteria and outcomes in Optilume (EVEREST) trials:

Optilume trial eligibility and outcomes: EVEREST first‑in‑human study enrolled men >50 years with IPSS ≥13, peak Qmax 5–15 mL/sec (minimum voided volume ≥125 mL), PVR ≤250 mL, prostate volume 20–80 g and prostatic urethra length 35–55 mm. The single‑arm study reported ≥40% IPSS improvement at 3 months in ~81% of participants and sustained improvements in a subset out to 4 years.IPSS ≥13; Qmax 5–15 mL/s; prostate volume 20–80 g

Evidence limited by single‑arm design; longer comparative studies needed.

inv-15: TULSA clinical evidence and limitations

TULSA evidence and key limitations relevant to coverage:

TULSA pivotal trial population and outcomes: Pivotal single‑arm trials enrolled men aged 45–80 with favorable to intermediate risk prostate cancer (Gleason Grade 1–2, clinical stage ≤T2b), PSA ≤15 ng/mL, and required appropriate biopsy/MRI staging; exclusions included prostate >90 cc and anatomic constraints. Trials report PSA and prostate volume reductions and mixed functional outcomes with some Grade 3 adverse events; lack of randomized comparators and limited long‑term oncologic follow‑up constrain conclusions.Prostate ≤90 cc (exclusion in pivotal trial); age 45–80

Existing data are mainly single‑arm; consider investigational designation or require enrollment in prospective studies for oncologic indications.

TULSA salvage and early studies: Small phase 1 and single‑center studies report feasibility for salvage TULSA after radiotherapy with variable oncologic control and limited sample sizes; further study required.

Evidence limited by small samples and lack of randomized comparators.

inv-16: Covered or recommended interventions

Procedures considered covered or recommended based on guidelines and policy revisions:

EAU guideline‑aligned interventions: EAU guidance supports enucleation techniques (Tm:YAG, diode laser enucleation) as alternatives to TURP for moderate‑to‑severe LUTS; Aquablation is an alternative for prostate volumes 30–80 mL; PAE may be an option for patients accepting potentially less optimal outcomes but should be performed only in units with highly trained teams.Aquablation: prostate 30–80 mL

Policy aligns select coverage to guideline recommendations.

PAE medical necessity (policy revision): Policy revision clarifies PAE is proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints (e.g., prostate size) or anesthesia risk (e.g., comorbidities).

Require documentation supporting ineligibility for standard procedures and informed counseling.

inv-17: Not medically necessary / Unproven procedures

Explicitly designated not medically necessary or unproven interventions:

Transurethral water jet ablation for malignant prostate tissue: Transurethral water jet ablation for treatment of malignant prostate tissue and all other indications not listed as proven in the policy is unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Policy language clarified to exclude malignant indications and other unproven uses.

Other technologies designated unproven: Transperineal focal laser ablation (TPLA/FLA), insertion of temporary prostatic urethral stent, ablation by magnetic field induction, transurethral drug‑coated balloon beyond established trial indications, and transurethral thermal ultrasound ablation (TULSA) are listed as unproven and not medically necessary for broad clinical use.

Routine use for localized prostate cancer or broad BPH indications not supported outside clinical trials.

This policy clarifies that several prostate procedures are considered unproven or not medically necessary when performed for indications outside the specific covered uses described elsewhere in the policy. Examples include transurethral ablation performed outside the referenced InterQual clinical coverage criteria and a range of novel focal or device-based interventions. These interventions are designated unproven because available evidence does not sufficiently demonstrate long‑term safety or effectiveness for the non‑covered uses listed in the policy, and therefore claims for those indications may be denied.

Providers requesting coverage for prostate procedures should ensure the indication aligns with the specific proven uses in this policy (for example, transurethral ablation when InterQual criteria are met). Documentation that demonstrates adherence to the applicable criteria is required for medical necessity review; procedures billed for indications explicitly identified as unproven or not medically necessary in the policy should not be expected to meet coverage criteria.

High‑energy water vapor thermotherapy for malignant prostate tissue is explicitly listed as unproven and not medically necessary because a literature search did not identify peer‑reviewed original data supporting its safety or efficacy for that indication.

Because there are no identified peer‑reviewed studies for treatment of malignant prostate tissue with high‑energy water vapor thermotherapy, the evidence base is insufficient to support coverage and clinical use for oncologic indications outside of a research setting.

Routine use of focal therapies (including focal laser ablation/FLA or transperineal focal laser ablation) for localized prostate cancer is not recommended outside of clinical trials or prospective comparative studies. Systematic reviews and guideline statements note limited, heterogeneous data and inconsistent oncologic effectiveness, supporting restriction of these approaches to research settings.

In practice, focal therapy trial populations and published series have varied inclusion criteria and short or inconsistent follow‑up; because high‑quality comparative evidence versus standard therapies (surgery, radiation, active surveillance) is lacking, routine substitution of focal therapy for established treatments is not supported by current evidence.

Many studies of emerging prostate procedures enrolled selected populations and excluded common clinical scenarios; therefore study findings may not generalize to routine practice. Examples of study‑based exclusions include large prostate volumes (>75–100 mL), presence of an obstructive median lobe, prior prostate surgery, urethral strictures, bladder stones, prostate cancer, and significant neurologic disease affecting voiding.

Because trials frequently used narrow eligibility criteria and small sample sizes, providers should be cautious when applying reported outcomes to broader patient groups and should document how an individual patient’s anatomy and prior history align with trial inclusion criteria when seeking prior authorization or coverage.

For Transurethral Thermal Ultrasound Ablation (TULSA), the policy identifies insufficient evidence regarding long‑term safety and efficacy. Available studies are mainly single‑arm or small series with limited follow‑up and lack randomized comparators, limiting confidence in oncologic control and functional outcomes.

Given these limitations, TULSA is listed among procedures for which longer‑term comparative data are needed before routine coverage can be supported; requests for TULSA should include detailed counseling documentation and consideration of investigational status.

Transurethral water jet ablation (for example, Aquabeam) is covered for benign prostatic hyperplasia when used for the proven BPH indications, but the policy explicitly excludes use of water jet ablation for treatment of malignant prostate tissue and for any other indications not listed as proven.

This explicit exclusion was added to clarify that malignant‑indication use of water jet or other transurethral ablation technologies lacks sufficient evidence and is considered unproven and not medically necessary.

The policy summarizes coverage status across multiple prostate procedures: transurethral ablation is covered when InterQual medical necessity criteria are met; cryoablation is covered only for recurrent prostate cancer diagnosed by biopsy; prostatic urethral lift (PUL/UroLift) is covered for FDA‑labeled indications with specific contraindications; transurethral water jet ablation and aquablation are covered for BPH in specified size ranges; and prostate artery embolization (PAE) is proven for select patients who are ineligible for other procedures. Several other technologies (e.g., TPLA/FLA, temporary stents, magnetic field induction ablation, drug‑coated balloons, TULSA for many indications) are designated unproven or not medically necessary.

Coverage decisions and prior authorization requirements will reflect these distinctions: proven, indication‑specific procedures require documentation demonstrating eligibility per the policy or InterQual criteria, while interventions listed as unproven or not medically necessary generally lack coverage except in approved clinical trial settings.

Randomized and observational evidence for cryoablation is heterogeneous and of generally low quality for many oncologic outcomes; thus cryoablation cannot be recommended as a general substitute for established primary treatments for localized prostate cancer. Systematic reviews report few RCTs and inconsistent outcome reporting, yielding uncertainty about comparative effectiveness.

Where cryoablation is requested as primary therapy for localized prostate cancer, expect requests for additional clinical justification; cryoablation is considered proven only for the specific covered indication of biopsy‑proven recurrent prostate cancer.

Comparative evidence comparing Prostate Artery Embolization (PAE) with transurethral resection of the prostate (TURP) has limitations. Systematic reviews and randomized trials show that PAE often yields similar patient‑reported symptom improvements but generally produces inferior objective functional outcomes (for example, lower Qmax and smaller reductions in prostate volume) and may have higher retreatment rates.

Because TURP typically provides greater improvements on many functional measures and has a more established long‑term evidence base, PAE is positioned in this policy as an option primarily for patients who are ineligible for other procedures (for surgical or anesthesia reasons) after counseling about comparative outcomes and retreatment risk.

The rationale for not covering certain emerging technologies is that the current evidence is limited by small sample sizes, single‑arm designs, short follow‑up, manufacturer involvement in some studies, and inconsistent or absent comparative data versus established treatments. These limitations prevent reliable conclusions about long‑term safety and effectiveness.

Accordingly, the policy restricts coverage of these technologies (for example, magnetic field induction ablation, temporary urethral stents, transurethral drug‑coated balloon, and TPLA for many indications) and recommends use within clinical trials or registries until higher‑quality comparative evidence is available.

Guideline bodies advise that whole‑gland or focal ablation procedures for localized prostate cancer should not be recommended outside of clinical trials because of a lack of high‑quality comparative data. The AUA/ASTRO guidance specifically recommends informing patients that ablation modalities lack robust data against surgery, radiation, or active surveillance and should be limited to research settings.

This policy aligns with those guideline recommendations by restricting routine coverage of whole‑gland and focal ablation approaches and emphasizing enrollment in prospective trials or registries for patients and providers pursuing these techniques.

Following the policy revision, Transurethral Thermal Ultrasound Ablation (TULSA) is included among procedures listed as unproven and not medically necessary for the indications covered by this policy due to insufficient evidence of long‑term safety and effectiveness and the predominance of non‑comparative studies.

Providers requesting coverage for TULSA should be aware that, absent stronger comparative or long‑term data, TULSA remains investigational for many prostate cancer and BPH applications and documentation should reflect investigational status or trial enrollment.

Applicable Procedure and Device Codes

Applicable CPT and related procedure codesmixed

0421T	Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed).
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance.
0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed.
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound
0714T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume less than 50mL.
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination.
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation.
0867T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50mL.
37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural road mapping, and imaging guidance necessary to complete the intervention: for tumors, organ ischemia, or infarction (when performed on prostate tissue).
51721	Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation, including suprapubic tube placement during the same session and placement of an endorectal cooling device, when performed.

1–10 of 21

1/3

Codes referenced elsewhere or not present in this excerptmixed

No codes listed

Procedure codes referenced (not listed)mixed

Not specified

Document does not list CPT/HCPCS/ICD-10 codes for PAE or TPLA in this section.

Applicable CPT Codes (added)CPT

51721
53865
53866
55881
55882

FDA product codes referencedmixed

LLZ	Product code referenced for powered laser devices
FRN	Product code referenced for powered laser devices
GEX	Product code referenced for powered laser devices
NOY	Product code referenced for microsphere products
PLP	Product code referenced for high intensity ultrasound ablation systems

Prostate volume exclusion for PUL

PUL FDA exclusion threshold> 100 cc

Other contraindications (selected)Active urinary tract infection; urethral conditions preventing device insertion; urinary incontinence due to incompetent sphincter; current gross hematuria

Age requirement (FDA-labeled)Men 45 years of age or older

Prostate volume eligibility ranges used in studies

Common prostate volume eligibility in trials30–80 cc

Broader ranges reported in literature/analyses

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior authorization, justification, and counseling required

Prior authorization is required for many transurethral and emerging prostate procedures. Requests must include clinical justification, evidence of counseling on benefits/risks and alternative therapies, and documentation that standard therapies were considered. When InterQual criteria apply (see policy references), include the InterQual determination or the clinical data elements that satisfy InterQual.

Obtain prior authorization before scheduling Aquablation, PAE, TPLA, TULSA, transurethral ablation CPT codes, and newly listed CPT codes (see Applicable Codes).
Document that the patient received counseling on: expected benefits, potential adverse events, retreatment risk, and alternative treatments (medical therapy, TURP, other minimally invasive options).

Prior Authorization

Prior authorization likely for emerging prostate procedures

Emerging prostate procedures (for example: Aquablation, PAE, TPLA, TULSA, transurethral thermal ultrasound, and other recently coded interventions) commonly require prior authorization because evidence, indications, and coding are evolving. Confirm coverage with UnitedHealthcare prior to performing these procedures.

Clinical Background and Definitions

Benign prostatic hyperplasia (BPH) is common in men over age 50 and can cause lower urinary tract symptoms (LUTS) such as weak urinary stream, urgency, frequency, nocturia, and urinary retention. Initial management typically includes conservative measures and medical therapy; procedural or surgical interventions are considered for patients with persistent symptoms that significantly affect quality of life or for complications such as recurrent urinary retention, recurrent urinary tract infections, or significant hematuria.

A range of minimally invasive and surgical options exist — including transurethral resection/enucleation, waterjet or thermal ablation, implant‑based approaches (PUL), embolization (PAE), and focal or whole‑gland ablative techniques — and each has a differing evidence base that informs the policy’s coverage determinations.

Definition — Cryoablation

DefinitionCryoablation (cryosurgery/cryotherapy) uses transrectal ultrasound-guided perineal probes through which very cold gas is passed to freeze and destroy prostate tissue

Typical usesUsed for focal or whole‑gland treatment in primary or recurrent prostate cancer; evidence heterogeneous with limited RCT data

Evidence limitationsSystematic reviews report observational studies and few/low-quality RCTs with inconsistent outcome reporting

Policy Updates

2025-07-01policy_revisionLatest

Removed coverage criteria for transperineal placement of biodegradable material and updated Prostatic Urethral Lift indication language to specify treatment of symptoms due to urinary outflow obstruction secondary to BPH, including lateral with or without median lobe hyperplasia, in men 45 years of age or older.

2025-07-01policy_clarification

Replaced language to clarify that transurethral water jet ablation for treatment of malignant prostate tissue and all other indications not listed as proven is unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for North Carolina Only)

Policy CodePolicy CSNCT0705.08

Change TypeMaterial revisions to coverage stance, indications, and code list

Effective DateJul 1, 2025

Next Review DateN/A

SourceLink

On This Page

Transurethral drug‑coated balloon (Optilume): Single‑arm and sham‑controlled trials show clinically meaningful sustained symptom improvement and preservation of sexual function through intermediate follow‑up, but lack of head‑to‑head comparisons versus established therapies limits definitive coverage conclusions.

Promising but further comparative and longer‑term data desirable.

20–150 cc (reported across various studies)

Smaller/other analytic rangesSome analyses report 50–80 g or >80 mL in subgroup assessments

PUL trial inclusion thresholds

IPSS (trial inclusion)IPSS > 12

Qmax (trial inclusion)Qmax ≤ 12–15 mL/s (trial-dependent)

Prostate volume (trial inclusion)Typically 30–80 cc depending on the study

Prostate volume subgroup reporting (>80 mL vs <80 mL)

Subgroup volume comparison reported> 80 mL vs < 80 mL reported in subgroup analyses for PAE outcomes

Study-level reporting heterogeneityOutcome reporting and groupings vary across studies (PV >80 mL vs <80 mL common)

Implication for selectionVolume-based subgroup analyses used to evaluate effectiveness in large vs small prostates

Prostate volume (trial inclusion) for TPLA

TPLA trial prostate volume inclusionProstate volume < 100 mL (Bertolo et al. randomized trial)

Typical TPLA exclusion examplesExclusions included prior prostate surgery, presence of median obstructive lobe, history of prostate cancer

Functional thresholds in TPLA trialsIPSS ≥ 10 and Qmax < 15 mL/s often required in reported trials

Aquablation prostate volume (30-80 mL)

Aquablation trial prostate volume range30-80 mL

EAU guideline noteEAU lists Aquablation as alternative for prostate volume 30-80 mL

Larger-prostate data are from single-arm/seriesSeparate series report outcomes for larger prostates but RCTs generally limited to ≤80 mL

Aquablation large prostate study range (80-150 cc)

Large-prostate study range reported80-150 cc in systematic reviews and single-arm series

Evidence type for large prostatesReported outcomes for 80–150 cc mostly from single-arm and observational studies rather than RCTs

RCT applicabilityMajor RCTs commonly limited to prostates ≤80 mL, so larger-range data are separate evidence streams

Verify plan coverage and medical necessity determination prior to procedure.

For newly listed CPT codes (see Applicable Codes), verify prior authorization requirements as they may vary by plan and state. Examples include codes added in the recent update (e.g., 51721, 55881, 55882).

Documentation Required

InterQual-based necessity for transurethral ablation

InterQual criteria are used to determine medical necessity for transurethral ablation and some other prostate procedures. Provide the InterQual decision or the full clinical data set used to apply InterQual when submitting authorization requests.

State which InterQual CP was applied (e.g., Procedures, Prostatectomy, Transurethral Ablation) and include date/version if available.
If an InterQual exception is requested, include supporting clinical rationale and objective measures. Examples of objective data: IPSS, Qmax, prostate volume, prior medication trials, and imaging/urodynamic findings.

Documentation Required

Aquablation and procedure‑specific required baseline data

For requests involving PAE or TPLA, include procedure-specific baseline data and objective measurements to support medical necessity and to allow outcomes assessment.

Required baseline data: IPSS (with date), Qmax (mL/s) and voided volume, post-void residual (PVR, mL), prostate volume (mL) by imaging, PSA value and date, IIEF/sexual function scores when relevant.
For Aquablation requests: include prostate volume, IPSS, Qmax, documented prior therapies, and rationale for choosing Aquablation over other options.

Documentation Required

Required clinical documentation for PAE/TPLA requests

Authorization for PAE/TPLA requires comprehensive clinical documentation including prior therapy trials, objective measures, and procedure rationale. Incomplete documentation may result in denial or delay.

Document prior conservative therapy and medication trials (alpha‑blocker and/or 5‑alpha‑reductase inhibitor) with dates and response.
For PAE, include imaging showing vascular anatomy as applicable, indication for embolization (e.g., poor surgical candidate), and explanation if TURP or other standard surgeries are not appropriate.
Include prior treatment history for BPH and reasons for retreatment if applicable (e.g., prior PAE with persistent symptoms).

Documentation Required

Required clinical measurements for review

Include the following objective clinical measurements in the authorization request so reviewers can assess necessity and expected benefit.

IPSS score and date (baseline and recent).
Qmax (mL/s) with voided volume and date.
Post‑void residual (PVR, mL) and prostate volume (mL) with imaging modality and date.
PSA value and date; IIEF or other sexual function scores when relevant.

Documentation Required

Clinical evidence and outcome documentation

Provide clinical evidence and anticipated outcomes in the request. Cite relevant comparative data when available, and disclose uncertainty about long‑term durability or retreatment risk which may affect coverage decisions.

If submitting for PAE, state understanding of higher retreatment rates vs TURP and provide patient‑specific rationale if selecting PAE.
For technologies with limited evidence (e.g., TULSA, TPLA, magnetic field induction), include supporting literature and plan for follow‑up/outcome measurement.

Note

Plan‑specific documentation and verification

Plan-specific rules may apply; always check member benefits and state fee-schedule restrictions. Codes not on a state Medicaid fee schedule may not be covered under that program even if listed in this policy.

Confirm member benefits, state-specific coverage limitations, and whether listed CPT codes (some marked with an asterisk) are reimbursable for the member's plan.
When in doubt, request precertification and include plan/contract identifiers with the authorization request.

Step Therapy

Step therapy / comparative and conservative therapy considerations

Step therapy considerations may apply, especially for PAE: many plans expect a documented trial of medical management and consideration of standard surgical options before approving PAE.

Document at least one adequate trial of alpha‑blocker therapy (and 5‑ARI if indicated) with dates and response.
If PAE is requested due to ineligibility for TURP or other standard surgery (e.g., high surgical/anesthesia risk), include objective evidence explaining why standard therapies are unsuitable.
Comparative requirements: provide prior procedural history (e.g., prior TURP, laser enucleation) and reasons for choosing embolization or alternative therapy.

Denial Risk

Insufficient evidence may lead to denial; provide robust justification

Insufficient or low‑quality evidence for some procedures (for example: certain focal ablation techniques, magnetic field induction ablation, temporary stents, transurethral drug‑coated balloons for some indications) may result in denial. Provide robust justification and high‑quality supporting evidence when requesting coverage for these indications.

When evidence is limited, include clinical trial data, registry participation, or rationale for off‑label use.
If prior authorization is denied for an unproven indication, consider enrollment in a clinical trial or provide additional documentation for peer review.

Definition — Rezūm (water vapor therapy)

DefinitionRezūm (water vapor therapy) uses thermal water vapor injected into the prostate to ablate tissue and reduce prostate volume associated with BPH

Target tissueCan treat central zone and/or middle (median) lobe hyperplasia as described in device literature

Outcome focusIntended to relieve LUTS by reducing obstructing tissue volume

Definition — Aquabeam (water jet ablation)

DefinitionAquabeam (water jet ablation) is a heat‑free robotic system that delivers a high‑velocity saline waterjet transurethrally to ablate benign prostate tissue

System nameAquaBeam Robotic System used in RCTs comparing to TURP

Indication contextStudied for moderate‑to‑severe LUTS due to BPH with prostate volumes typically within trial-specified ranges

Definition — TPLA (transperineal focal laser ablation)

DefinitionTransperineal focal laser ablation (TPLA/FLA) delivers laser energy via an optical fiber inserted through the perineal skin under transrectal ultrasound guidance to ablate targeted prostate tissue

Clinical roles under studyInvestigated for focal treatment of localized prostate cancer and for BPH symptom control with potential ejaculatory preservation

Evidence summaryRCTs show TPLA may preserve ejaculation but are inferior to TURP for some efficacy outcomes; long‑term oncologic data limited

Definition — Prostatic urethral lift (UroLift)

DefinitionProstatic urethral lift (PUL/UroLift) places permanent implants to hold open lateral and median prostatic lobes to reduce urethral obstruction

Intended effectRelieves urinary outflow obstruction due to BPH while preserving sexual function in many patients

FDA‑labeled population noteIndicated in men ≥45 years when contraindications (eg, prostate volume >100 cc) are absent

Definition — Prostate artery embolization (PAE)

DefinitionProstate artery embolization (PAE) is an endovascular procedure that injects microspheres into prostatic arteries to occlude vessels and cause gradual prostate shrinkage

Technical detailsReported particle sizes range from 50–500 μm; typically performed via femoral access with bilateral embolization

Clinical contextMay offer perioperative advantages (less bleeding, shorter hospitalization) but may have higher retreatment rates than TURP

Definition — Prostatic Urethral Lift (additional trial context)

Trial context (PUL) — inclusion metricsTrials enrolled men ≥50 years with IPSS >12, Qmax thresholds and prostate volumes typically 30–80 cc

Evidence findingsRandomized and prospective trials (including sham‑controlled RCT) show durable symptom improvement and sexual function preservation up to 5 years in selected patients

Comparative noteComparative studies show TURP superior for some objective flow metrics while PUL has faster recovery and better sexual outcomes in trials

Definition — Aquablation (AquaBeam Robotic System)

DefinitionAquablation (AquaBeam Robotic System) is an image‑guided, robotically executed transurethral waterjet tissue ablation system for BPH

RCT evidenceRCT data comparing Aquablation to TURP report similar symptom improvements up to 5 years with possible ejaculatory advantages

Volume limitations in trialsMajor RCTs limited to prostates ≤80 mL; larger‑volume evidence comes from nonrandomized series

Definition — PAE (additional context)

Definition/contextPAE — endovascular embolization of prostatic arteries using particulate embolic agents to reduce prostate volume and LUTS; may be offered for large glands or high surgical risk patients

Outcome tradeoffsProvides perioperative benefits but may have higher retreatment rates and uncertain long‑term objective outcomes versus TURP

Selection noteOften recommended in centers with experienced interventional radiology teams

Definition — Cryoablation (additional context)

Additional cryoablation contextCryoablation evidence consists largely of observational studies with few RCTs; Cochrane and other reviews report low‑quality evidence and inconsistent reporting

Clinical safety concernsReported adverse events include urinary retention, erectile dysfunction, fistula, stricture, infection, hematuria, and perineal pain

Oncologic outcome uncertaintyBiochemical and survival outcomes reported variably; high heterogeneity limits firm conclusions

Definition — PAE (technical details)

Technical details — PAEEmbolization often uses particles 50–500 μm delivered via femoral access with intraprocedural imaging and roadmapping

Bilateral embolization typicalMost studies report successful bilateral embolization as standard technique

Measured outcomesCommonly reported outcomes include IPSS, PVR, Qmax, PSA, and retreatment rates

Definition — TPLA / FLA

Definition — TPLA/FLATransperineal (focal) laser ablation delivers laser energy via perineal access under imaging guidance to ablate targeted prostate tissue for focal therapy

Indications under studyInvestigated for focal treatment of localized prostate cancer and for BPH symptom control with possible ejaculatory preservation

Evidence qualityEvidence limited; small RCTs show inferiority to TURP on some efficacy outcomes but better sexual preservation

Definition — IPSS

IPSS definitionInternational Prostate Symptom Score — patient‑reported symptom severity metric used as a primary outcome in trials

Use in trialsUsed as primary efficacy endpoint in many device and procedure studies (eg, PUL, Aquablation, Optilume)

InterpretationPercent or point improvements in IPSS commonly reported to measure clinical benefit

Definition — Qmax

Qmax definitionQmax is peak urinary flow rate measured by uroflowmetry and is an objective functional outcome in BPH studies

Trial thresholdsMany trials use Qmax thresholds for inclusion (eg, ≤12–15 mL/s) and report Qmax change as efficacy outcome

Clinical interpretationImprovements in Qmax support objective symptom relief but may differ from patient‑reported outcomes

Definition — EVEREST (Optilume) study

EVEREST study — populationEVEREST was a first‑in‑human, prospective single‑arm study of Optilume including participants age ≥50 with IPSS ≥13, Qmax 5–15 mL/s, prostate volume 20–80 g

Primary endpoints and follow upPrimary endpoint ≥40% IPSS improvement at 3 months; follow up reported through 4 years in subsets

Safety signalsReported AEs included postprocedural hematuria, urinary retention, UTI and ejaculation disorders; longer‑term comparative data limited

Definition — TULSA

TULSA definitionTULSA (Transurethral Thermal Ultrasound Ablation) uses a rotating transurethral ultrasound probe with MRI thermometry to deliver precise thermal ablation to prostate tissue

Clinical applicationStudied for whole‑gland or partial gland ablation in localized prostate cancer with MRI guidance

Evidence limitationsTrials are largely single‑arm with limited comparative oncologic outcomes and some Grade 3 adverse events reported in pivotal studies

Definition — Aquablation descriptive definition

Aquablation descriptionAquablation is a waterjet‑based robotic transurethral procedure that ablates prostate tissue using an image‑guided robotic waterjet

Comparative evidenceRandomized controlled data comparing Aquablation to TURP show similar IPSS and uroflow improvements up to 5 years

Patient selectionRCTs enrolled patients aged 45–80 and prostate sizes generally up to 80 mL; separate series assess larger glands

Definition — PAE descriptive definition and patient selection note

PAE description and selection notePAE is a minimally invasive radiologic embolization procedure for men with moderate‑to‑severe LUTS who prefer less invasive options or are poor surgical candidates; may be appropriate for large prostates or those with comorbidities

Comparative counseling needPatients should be counseled that PAE can offer perioperative advantages but may have higher retreatment rates and often inferior objective flow outcomes compared with TURP

Center experience requirementEAU and evidence summaries recommend PAE be performed in units with highly trained teams

2025-07-01policy_revision

Revised position on prostate artery embolization (PAE) to state PAE is proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints or anesthesia risk.

2025-07-01coding_update

Added CPT codes 51721, 53865, 53866, 55881, and 55882 to the applicable codes list (notation added that CPT codes 51721, 55881, and 55882 are not on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by the State of North Carolina Medicaid Program).